Updates, Insights & Perspectives

Summary Onconox Inc. has appointed biotech executive Geoff Muckle as CEO to strengthen the company’s leadership and drive OCN001 toward first-in-human studies in 2026. Geoff brings more than two decades of oncology and biotech experience spanning Roche, Champions Oncology, and Link Medical Solutions, and will lead the company’s evolution from a single-asset entity to a scalable platform-driven biotech. Onconox Inc., a biotechnology company developing precision, low-burden the

Summary Onconox Inc. has appointed Ajay Kambhampati as a Non-Executive Director. Ajay, one of the company’s original seed investors, brings more than 25 years of experience across healthcare technology, investment, and corporate finance. His strategic, financial, and operational expertise will support Onconox as it advances OCN001 through IND-enabling development and toward future clinical evaluation. Onconox Inc., a biotechnology company advancing a novel therapeutic candida

Summary Onconox Inc. has selected Vimta Labs Ltd as its contract research organization (CRO) to conduct a pivotal 13-week inhalation toxicology study for its lung-cancer therapeutic candidate OCN001. Vimta’s established capability in inhalation product analysis, GLP-certified facilities, and comprehensive preclinical service suite enables Onconox to advance the program toward IND submission with rigorous, regulatory-aligned safety data. Onconox Inc., a biotechnology company d

Summary Onconox Inc. has appointed Professor Justin Stebbing, a leading global oncologist, as Scientific and Medical Advisor to help shape the company’s scientific and clinical strategy for OCN001. His expertise strengthens Onconox’s preparations for IND-enabling activities and future clinical development. Both CEO Dr Sitaram Velaga and Professor Stebbing commented on the importance of this appointment. Onconox Inc., a biotechnology company dedicated to developing a novel the

Summary Onconox Inc. has successfully closed its seed funding round, securing capital to advance OCN001 through the next phase of its IND-enabling program. The raise builds on substantial preclinical progress already achieved under Kenox Pharmaceuticals, including a successful pre-IND meeting in 2021, and positions Onconox to accelerate the asset toward clinical evaluation. Onconox Inc., a biotechnology company dedicated to the development of a novel therapeutic candidate for

Summary Kenox Pharmaceuticals has established Onconox Inc. as a wholly owned subsidiary to advance OCN001, its investigational lung cancer therapy, into clinical development. The decision follows significant preclinical progress achieved within Kenox, including a successful pre-IND meeting in 2021. Full IP and development rights for OCN001 have been transferred to Onconox, enabling dedicated focus and streamlined progression toward clinical evaluation. Kenox Pharmaceuticals,